DMYD-B.ST

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$38M	+1166.7%	$-1.60	$-1.60–$-1.60	—	1
2028	$154307	-99.6%	$-0.49	$-0.49–$-0.49	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$2.39

Price

$1.00

Implied upside

+140%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
DMYD-B.STDiamyd Medical AB (publ)	$1.01	-0.20%	$154M	—
BICO.STBICO Group AB (publ)	$20.45	-0.24%	$1.4B	—
BINV.STBioInvent International AB (publ)	$22.60	+1.12%	$1.5B	—
CANTA.STCantargia AB (publ)	$1.58	-0.69%	$445M	—
EGTX.STEgetis Therapeutics AB (publ)	$7.87	-1.13%	$3.7B	—
GENO.STGenovis AB	$20.30	+1.00%	$1.3B

Source: Financial Modeling Prep · peers by sector/industry

Diamyd Medical AB (publ)

Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.

www.diamyd.com

Employees: 44
IPO / List date: May 20, 2013
HQ: SE

Held by traders on TradeandTell

No one on the platform currently holds DMYD-B.ST.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in DMYD-B.ST as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded DMYD-B.ST yet.